A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

Part of paid clinical trials in Glendale, Arizona.

Sponsor
UCB Biopharma SRL
Study ID
NCT04436640
Phase
PHASE3
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bimekizumab — DRUG
    Subjects will receive bimekizumab at prespecified time-points.

Study Details

The purpose of the study is to demonstrate the long-term safety, tolerability and efficacy of bimekizumab in patients with active axial spondyloarthritis (axSpA, also known as radiographic axSpa (r-axSpA)) including ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (nr-axSpa).

Key Dates

Start date
Jun 16, 2020
Status verified
May 2026
Primary completion
Aug 7, 2026
Completion
Aug 7, 2026

Study Design

Enrollment
508 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bimekizumab
    Subjects will receive bimekizumab throughout the Treatment Period.

Primary Outcome Measure

Percentage of participants with treatment-emergent adverse events (TEAEs) during the study [ Time Frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 180) ]

Locations (10)

FacilityCityStateZIPSite coordinators
As0014 50062GlendaleArizona85306-
As0014 50052PhoenixArizona85032-
As0014 50060UplandCalifornia91786-
As0014 50059Ormond BeachFlorida32174-
As0014 50056SarasotaFlorida34239-
As0014 50015HagerstownMaryland21740-
As0014 50016St LouisMissouri63141-
As0014 50055PortlandOregon97239-
As0014 50020DuncansvillePennsylvania16635-
As0014 50057DallasTexas75231-

Find similar trials in Glendale, AZ

By research site
As0014 50062· Glendale, AZAs0014 50052· Phoenix, AZAs0014 50060· Upland, CAAs0014 50059· Ormond Beach, FLAs0014 50056· Sarasota, FLAs0014 50015· Hagerstown, MD

Related Studies